From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 9.2%. This performance was worse than the S&P 500’s 1.8% loss.
Discover GLOBUS MEDICAL INC - A, an undervalued growth gem. NYSE:GMED is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Medical device company Globus Medical (NYSE:GMED) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.6% year on year to $657.3 million. The company expects the full year’s revenue to be around $2.68 billion, close to analysts’ estimates. Its non-GAAP profit of $0.84 per share was 12.2% above analysts’ consensus estimates.
